JP2020524141A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524141A5
JP2020524141A5 JP2019569454A JP2019569454A JP2020524141A5 JP 2020524141 A5 JP2020524141 A5 JP 2020524141A5 JP 2019569454 A JP2019569454 A JP 2019569454A JP 2019569454 A JP2019569454 A JP 2019569454A JP 2020524141 A5 JP2020524141 A5 JP 2020524141A5
Authority
JP
Japan
Prior art keywords
cancer
composition
seq
polypeptide
elane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569454A
Other languages
English (en)
Japanese (ja)
Other versions
JP7189160B2 (ja
JP2020524141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037800 external-priority patent/WO2018232273A1/en
Publication of JP2020524141A publication Critical patent/JP2020524141A/ja
Publication of JP2020524141A5 publication Critical patent/JP2020524141A5/ja
Priority to JP2022192891A priority Critical patent/JP7529754B2/ja
Application granted granted Critical
Publication of JP7189160B2 publication Critical patent/JP7189160B2/ja
Priority to JP2024119305A priority patent/JP2024150679A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569454A 2017-06-15 2018-06-15 がんを処置するための方法および組成物 Active JP7189160B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022192891A JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物
JP2024119305A JP2024150679A (ja) 2017-06-15 2024-07-25 がんを処置するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520325P 2017-06-15 2017-06-15
US62/520,325 2017-06-15
US201762610711P 2017-12-27 2017-12-27
US62/610,711 2017-12-27
PCT/US2018/037800 WO2018232273A1 (en) 2017-06-15 2018-06-15 Methods and compositions for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022192891A Division JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020524141A JP2020524141A (ja) 2020-08-13
JP2020524141A5 true JP2020524141A5 (https=) 2021-09-09
JP7189160B2 JP7189160B2 (ja) 2022-12-13

Family

ID=64659547

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019569454A Active JP7189160B2 (ja) 2017-06-15 2018-06-15 がんを処置するための方法および組成物
JP2022192891A Active JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物
JP2024119305A Pending JP2024150679A (ja) 2017-06-15 2024-07-25 がんを処置するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022192891A Active JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物
JP2024119305A Pending JP2024150679A (ja) 2017-06-15 2024-07-25 がんを処置するための方法および組成物

Country Status (9)

Country Link
US (1) US12564623B2 (https=)
EP (2) EP4292606B1 (https=)
JP (3) JP7189160B2 (https=)
CN (1) CN111032075A (https=)
AU (1) AU2018285710B2 (https=)
CA (1) CA3066738A1 (https=)
DK (1) DK3638293T5 (https=)
ES (2) ES2962985T3 (https=)
WO (1) WO2018232273A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CA3184037A1 (en) * 2020-08-18 2022-02-24 Onchilles Pharma, Inc. Modified serine protease proproteins
EP4199947A4 (en) * 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113736742B (zh) * 2021-09-08 2023-07-21 河南省医药科学研究院 Prtn3基因作为肿瘤免疫治疗中激活细胞毒性免疫细胞靶点的应用
CN115040642B (zh) * 2022-06-30 2025-03-28 德博尔(成都)生物科技有限公司 一种胰弹性蛋白酶的新用途
CN118443941A (zh) * 2024-04-29 2024-08-06 山东大学齐鲁医院 中性粒细胞作为诊疗膀胱癌的靶标的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA27035C2 (uk) 1990-08-03 2000-02-28 Вертекс Фармас'Ютікалс Інкорпорейтід Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
US5698518A (en) * 1994-03-30 1997-12-16 Oklahoma Medical Research Foundation Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists
AU2003231981A1 (en) * 2002-03-29 2003-10-13 Incyte Corporation Protein modification and maintenance molecules
CA2500405A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
JP4408615B2 (ja) 2002-10-07 2010-02-03 独立行政法人科学技術振興機構 好酸球カチオン性タンパク質を含有する組成物
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1649289B1 (en) 2003-07-21 2008-10-22 Roche Diagnostics GmbH Use of proteins proteinase 3 (prn3) and leukocyte elastase inhibitor (ileu) as a marker for colorectal cancer
US7432419B2 (en) * 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
US20060008891A1 (en) 2004-06-23 2006-01-12 The Government Of Usa As Repersented By The Secretary, Department Of Health And Human Services Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR)
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2010009368A2 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2016125330A1 (ja) 2015-02-02 2016-08-11 原 英彰 網膜再生促進薬

Similar Documents

Publication Publication Date Title
JP2020524141A5 (https=)
Jiang et al. Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy
JP2017529059A5 (https=)
WO2012094653A4 (en) Compositions and methods for macromolecular drug delivery
US20170260246A1 (en) Carcinoma homing peptide (chp), its analogs, and methods of using
KR102050621B1 (ko) Rtrail 변이체 및 이의 모노메틸 오리스타틴 e 접합체
PL238187B1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
US12377161B2 (en) TNF-alpha immunoconjugate therapy for the treatment of brain tumors
WO2016186445A1 (ko) 암 세포 표적용 펩타이드 및 이의 용도
JP2023145635A (ja) 免疫調節特性を有するペプチド
Sui et al. Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy
Tao et al. Multivalent assembly of nucleolin-targeted F3 peptide potentiates TRAIL's tumor penetration and antitumor effects
Beswick Bicycles—An entirely new class of therapeutics
TW201809013A (zh) 用於藥物遞送之抗體融合蛋白
CN116832177A (zh) 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用
CN105985447B (zh) 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途
KR20240113641A (ko) 종양 표적 전달체, mmp 절단서열, 항암펩티드 및 세포투과펩티드를 포함하는 종양 표적화 항체 융합단백질 플랫폼
Xu et al. Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels
Maruyama et al. Albumin Fusion Protein
WO2018219301A1 (zh) 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US20170037091A1 (en) Sty peptides for inhibition of angiogenesis
JPWO2020132465A5 (https=)
CN110914421A (zh) 选择性细胞死亡诱导酶系统
RU2021108002A (ru) Пептидные терапевтические препараты для лечения рака и варианты их применения